Pharmaceuticals, Biotechnology and Life Sciences
Phase 1/2 clinical study in patients with advanced solid tumor expected to start in 2Q2022 SEONGNAM-SI, South Korea–(BUSINESS WIRE)–Qurient Co.…
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in…
Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savingsCAMBRIDGE, Mass and…
TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)…
Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH. As a result of the acquisition, Medix…
Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in…
Hikma Pharmaceuticals PLC has completed acquisition of the Canadian assets of Teligent Inc. for $45.75 million. The acquisition marks Hikma’s…
Pfizer said Wednesday that the results from multiple studies showed the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron.
Gilead Sciences was reported as filing a lawsuit against certain suppliers and distributors of selling fake versions of its HIV…
The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat, a novel, orally active Neutrophil Elastase (NE) inhibitor in hospitalized COVID-19 Respiratory Disease patients.